The management of hypertensive disease in Black patients

QJM: An International Journal of Medicine

Volumn 92, Issue 4, 1999, Pages 187-192

  Gibbs, C R ^a   Beevers, D G ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ETHNIC DIFFERENCE; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; NEGRO; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0032915206     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/92.4.187     Document Type: Review

References (57)

1. Cruickshank JK, Beevers DG, Osbourne VL, Haynes RA, Corlett JC, Selby S. Heart attack, stroke, diabetes and hypertension in West Indians, Asians and whites in Birmingham, England. Br Med J 1980; 281:1108.
2. Shulman NB, Hall WD. Renal vascular disease in African-Americans and other racial minorities. Circulation 1991; 83:1477-9.
3. Hammond IW, Devereux RB, Alderman MH, Lutas EM, Spitzer MC, Crowley JS, et al. The prevalence and correlates of echocardiographic left ventricular hypertrophy among employed patients with uncomplicated hypertension. J Am Coll Cardiol 1986; 7:639-50.
4. Miller JM. Diabetes mellitus and hypertension in black and white populations. South Med J 1996; 79:1229-35.
5. A review on ethnic differences in plasma triglycerides and high-density-lipoprotein cholesterol: is the lipid pattern the key factor for the low coronary heart disease rate in people of African origin? Eur J Epidemiol 1998; 14:9-21.
6. Lip GYH, Beevers M, Beevers DG. Survival and prognosis of 315 patients with malignant-phase hypertension. J Hypertens 1995; 13:915-24.
7. Poulter NR, Khaw KT, Hopwood BE, Mugabi M, Peart WS, Rose G, Sever PS. The Kenyan Luo migration study: observations on the initiation of a rise in blood pressure. Br Med J 1990; 300:967-72.
8. Freis ED, Materson BJ, Flamenbaum W. Comparison of propanalol or hydrochlorthiazide alone for treatment of hypertension: III. Evaluation of the renin-angiotensin system. Am J Med 1983; 74:1029-41.
9. + and cell membrane adenosine triphosphatase activity in essential hypertension in blacks. J Hypertens 1992; 10:571-8.
10. Munro-Faure AD, Beilin LJ, Bulpitt CJ, Coles EC, Dollery CT, Gear JSS, et al. Comparison of black and white patients attending hypertension clinics in England. Br Med J 1979; 1:1044-7.
11. Campese VM, Parise M, Karubian F, Bigazzi R. Abnormal renal haemodynamics in black salt-sensitive patients with hypertension. Hypertension 1991; 18:805-12.
12. Zavaroni I, Coruzzi P, Bonini L et al. Association between salt sensitivity and insulin concentrations in patients with hypertension. Am J Hypertens 1995; 8:855-8.
13. MacGregor GA, Markandu ND, Best FE, Elder DM, Cam JM, Sagnella GA, et al. Double-blind randomised crossover trial of moderate sodium restriction in essential hypertension. Lancet 1982; i:351-5.
14. MacGregor GA, Markandu ND, Sagnella GA, Singer DR, Cappuccio FP. Double-blind study of three sodium intakes and long-term effects of sodium restriction in essential hypertension. Lancet 1989; ii:1244-7.
15. Cappuccio FP, Markandu ND, Carney C, Sagnella GA, MacGregor GA. Modest salt restriction in older people. J Hypertens 1997; 15(suppl 4):S3.
16. MacGregor GA, Smith SJ, Markandu ND, Banks RA, Sagnella GA. Moderate potassium supplementation in essential hypertension. Lancet 1982; ii:567-70.
17. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Urinary and serum electrolytes in untreated black and white hypertensives. J Chron Dis 1987; 40:839-47.
18. Ganguli MC, Grimm RH Jr, Svendsen KH, Flack JM, Grandits GA, Elmer PJ. Higher education and income are related to a better Na : K ratio in blacks: baseline results of the Treatment of Mild Hypertension Study (TOMHS) data. Am J Hypertens 1997; 10:979-84.
19. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program II. Mortality by race-sex and age. JAMA 1979; 242:2572-7.
20. Oberman A, Wassertheil-Smoller S, Langford HG, Blaufox MD, Davis BR, Blaszkowski T, et al. Pharmocologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status. Ann Intern Med 1990; 112:89-95.
21. Tyroler HA, Heyden S, Hames CG. Weight and Hypertension. Evans County studies of blacks and whites. In: Paul O, ed. Epidemiology and Control of Hypertension. New York, Stratton Intercontinental Medical Book Corp, 1975:177-204.
22. Klatsky AL, Friedman GD, Siegelaub AB, Gerard MJ. Alcohol consumption and blood pressure. Kaiser-Permanente Multiphasic Health Examination data. N Engl J Med 1977; 296:1194-200.
23. Boyer JL, Kasch FW. Exercise therapy in hypertensive men. JAMA 1970; 211:1668-71.
24. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Comparison of propanalol and hydrochlorthiazide for the initial treatment of hypertension: I. Results of short-term titration with emphasis on racial differences in response. JAMA 1982; 248:1996-2003.
25. Stewart DE, Ikram H, Espiner EA, Nicholls MG. Arrhythmogenic potential of diuretic-induced hypokalaemia in patients with mild hypertension and ischaemic heart disease. Br Heart J 1985; 54:290-7.
26. Hypertension Detection and Follow-up Program Cooperative Group. Blood pressure studies in 14 communities: a two-stage screen for hypertension. JAMA 1977; 237:2385-91.
27. Bosman AR, Goldberg B, McKechnie JK, Offermeier J, Oosthuizen OJ. South African multicentre study of metoprolol and propranalol in essential hypertension. S Afr Med J 1977; 51:57-61.
28. Abson CP, Levy LM, Eyherabide G. Once-daily atenolol in hypertensive Zimbabwean blacks. A double-blind trial using two different doses. S Afr Med J 1981; 60:47-8.
29. Flamenbaum W, Weber MA, McMahon FG, Materson BJ, Carr AA, Poland M. Monotherapy with labetalol compared with propanalol: differential effects by race. J Clin Hypertens 1985; 1:56-9.
30. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Efficacy of nadolol alone and combined with bendroflumethiazide and hydralazine for systemic hypertension. Am J Cardiol 1983; 52:1230-7.
31. Drayer JIM, Weber MA. Monotherapy of essential hypertension with a converting-enzyme inhibitor. Hypertension 1983; 5(suppl 3):108-13.
32. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorthiazide. Br J Clin Pharmacol 1982; 14(suppl 2):97-101.
33. Ventura HO, Frohlich ED, Messerli FH, Kobrin I, Kardon MB. Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension. Am J Cardiol 1985; 55:1023-6.
34. Weir MR, Gray JM, Paster R, Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients. The Trandolapril Multicentre Study Group. Hypertension 1995; 26:124-30.
35. Taguma Y, et al. Effect of captopril on heavy proteiuria in azotaemic diabetes. N Engl J Med 1985; 313:1617-20.
36. Lewis EJ, et al. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329:1456-62.
37. Powers DR, Wallin JD. End-stage renal disease in specific ethnic and racial groups. Arch Intern Med 1998; 158:793-800.
38. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60:8-13.
39. Gainer JV, Nadeau JH, Ryder D, Brown NJ. Increased sensitivity to bradykinin among African Americans. J Allergy Clin Immunol 1996; 98:283-7.
40. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med 1990; 150:1707-13.
41. Materson BJ, Reda DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328:914-21.
42. Moser M, Lunn J, Materson BJ. Comparative effects of diltiazem and hydrochlorthiazide in blacks with systemic hypertension. Am J Cardiol 1985; 56:101H-4H.
43. Olutade BO, Hall WD, Hildebrandt K, et al. Efficacy of nifedipine GITS vs hydrochlorthiazide in the management of mild to moderate hypertension in the black hypertensive. J Hum Hypertens 1989; 4:196.
44. Carr AA, Prisant LM. The new calcium antagonist isradipine. Effect on blood pressure and the left ventricle in black hypertensive patients. Am J Hypertens 1990; 3:8.
45. Resnick LM, Laragh JH, Sealey JE, et al. Divalent cations in essential hypertension. Relations between serum ionized calcium, magnesium and plasma renin activity. N Engl J Med 1985; 309:888.
46. Nicholson JP, Resnick LM, Lahargh JH. The antihypertensive effect of verapamil at extremes of dietary sodium intake. Ann Intern Med 1987; 107:329-34.
47. Kubo SH, Cody RJ, Covit AB, Feldschuh J, Laragh JH. The effects of verapamil on renal blood flow, renal function and neurohormonal profiles in patients with moderate to severe hypertension. J Clin Hypertens 1986; 53:38-46.
48. Epstein M. Calcium antagonists and the kidney: implications for renal protection. J Cardiovasc Pharmacol 1991; 18:S64-S70.
49. Zucchelli P, Zuccala A, Borghi M, et al. Long-term comparison between coptopril and nifedipine in the progression of renal insufficiency. Kidney Int 1992; 42:452-8.
50. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997; 29:744-50.
51. Veterans Administration Cooperative Study Group on Antihypertensive Agents: Comparison of prazosin with hydralazine in patients receiving hydrochlorthiazide. A randomized, double-blind clinical trial. Circulation 1981; 64:772-9.
52. Himmelmann A, Svensson A, Bergbrnat A, Hansson L. Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension. J Hum Hypertens 1996; 10:729-34.
53. Tedesco MA, Ratti G, Aquino D, Limongelli G, Di Salvo G, Mennella S, et al. J Hum Hypertens 1998; 12:in press.
54. Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, et al. The Losartan Intervention for Endpoint reduction (LIFE) in hypertension study: rationale design and methods. The LIFE study Group. Am J Hypertens 1997; 10:705-13.
55. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45:861-7.
56. Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18:797-810.
57. Sharma PK, Yium JJ. Angioedema associated with angiotensin II receptor antagonist losartan. South Med J 1997; 90:552-3.